© 2020


From Basic Research to Clinical Applications

  • Israel Vlodavsky
  • Ralph D. Sanderson
  • Neta Ilan

Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 1221)

Table of contents

  1. Front Matter
    Pages i-xviii
  2. Historical and General Background

    1. Front Matter
      Pages 1-1
    2. Israel Vlodavsky, Neta Ilan, Ralph D. Sanderson
      Pages 3-59
    3. Ulf Lindahl, Jin-Ping Li
      Pages 61-69
    4. Mayank Khanna, Christopher R. Parish
      Pages 71-96
    5. Felipe C. O. B. Teixeira, Martin Götte
      Pages 97-135
  3. Crystal Structure, Substrate Specificity and Gene Regulation

    1. Front Matter
      Pages 137-137
    2. Shaun M. Gaskin, Tatiana P. Soares Da Costa, Mark D. Hulett
      Pages 189-229
  4. Tumor Biology

    1. Front Matter
      Pages 251-251
    2. Neta Ilan, Udayan Bhattacharya, Uri Barash, Ilanit Boyango, Yifat Yanku, Miri Gross-Cohen et al.
      Pages 253-283
    3. Guido David, Pascale Zimmermann
      Pages 285-307
    4. Anurag Purushothaman, Ralph D. Sanderson
      Pages 331-349
    5. Anqi Xiong, Argyris Spyrou, Karin Forsberg-Nilsson
      Pages 365-403
    6. Giuliana Cassinelli, Cinzia Lanzi
      Pages 405-431
  5. Immune Cells

    1. Front Matter
      Pages 433-433

About this book


Proteases and their involvement in cancer progression have been well addressed and documented; however, the emerging premise presented within this book is that Heparanase is a master regulator of aggressive cancer phenotypes and crosstalk with the tumor microenvironment. This endoglycosidase contributes to tumor-mediated remodeling of the extracellular matrix and cell surfaces, augmenting the bioavailability of pro-tumorigenic and pro-inflammatory growth factors and cytokines that are bound to Heparan sulfate. Compelling evidence ties Heparanase with all steps of tumor progression including tumor initiation, growth, angiogenesis, metastasis, and chemoresistance, supporting the notion that Heparanase is an important contributor to the poor outcome of cancer patients and a validated target for therapy. Unlike Heparanase, heparanase-2, a close homolog of Heparanase, lacks enzymatic activity, inhibits Heparanase, and regulates selected genes that promote normal differentiation and tumor suppression. Written by internationally recognized leaders in Heparanase biology, this volume presents a comprehensive understanding of Heparanase’s multifaceted activities in cancer, inflammation, diabetes and other diseases, as well as its related clinical applications to scientists, clinicians and advanced students in cell biology, tumor biology and oncology.


heparanase carcinoma sarcoma cell microenvironment metastasis angiogenesis hematological malignancies heparin sulfate

Editors and affiliations

  • Israel Vlodavsky
    • 1
  • Ralph D. Sanderson
    • 2
  • Neta Ilan
    • 3
  1. 1.Technion Integrated Cancer Center (TICC) Rappaport Faculty of MedicineTechnion-Israel Institute of TechnologyHaifaIsrael
  2. 2.Department of PathologyUniversity of Alabama at BirminghamBirminghamUSA
  3. 3.Technion Integrated Cancer Center (TICC) Rappaport Faculty of MedicineTechnion-Israel Institute of TechnologyHaifaIsrael

About the editors

Israel Vlodavsky is a Professor of Cancer and Vascular Biology at Technion- Israel Institute of Technology’s Rappaport Faculty of Medicine and Technion Integrated Cancer Center (TICC). Vlodavsky’s discovery of the extracellular matrix as a reservoir for bioactive molecules provided the basis for the current appreciation of the tumor microenvironment and its significance in cancer progression and treatment. A pioneering achievement of Vlodavsky is the cloning and characterization of heparanase, the predominant enzyme that degrades heparan sulfate and fulfills important roles in tissue remodeling, cancer metastasis, angiogenesis, inflammation, diabetes, and kidney dysfunction. Through the combination of basic and translational research, Vlodavsky is the leading scientist in this area of research, offering basic insights and new treatment strategies for various cancers and other diseases. He earned his bachelor’s and Master’s degrees from The Hebrew University of Jerusalem, and Ph.D. from the Weizmann Institute, Rehovot, Israel.
Ralph Sanderson is the UAB Endowed Professor of Cancer Pathobiology and Director, Division of Molecular and Cellular Pathology, Department of Pathology, UAB O’Neal Comprehensive Cancer Center, University of Alabama at Birmingham. Sanderson earned a B.S. from the University of Alabama, and a Ph.D. at the University of Alabama at Birmingham. His research focuses on determining how tumor-host cell interactions mediated by heparan sulfate and the enzyme heparanase regulate the tumor microenvironment and promote tumor progression, and to use that knowledge to design new cancer therapies.

Neta Ilan is a Senior Researcher at the Rappaport Faculty of Medicine and the Technion Integrated Cancer Center (TICC), Haifa, Israel. Neta earned a bachelor’s degree in Agricultural Sciences and a Master’s degree in Biotechnology from the Hebrew University of Jerusalem. Neta completed his education at the Hebrew University, with a doctorate in Animal Sciences, working on manipulation of the mammary gland of transgenic animals. He did his postdoctoral training at Yale University, focusing on tumor angiogenesis. His current research focuses on the mode of action and role of heparanase in cancer initiation, growth, and metastasis in order to address problems in the prevention, management, and treatment of cancer.

Bibliographic information

  • Book Title Heparanase
  • Book Subtitle From Basic Research to Clinical Applications
  • Editors Israel Vlodavsky
    Ralph D. Sanderson
    Neta Ilan
  • Series Title Advances in Experimental Medicine and Biology
  • Series Abbreviated Title Adv Exp Med Biol
  • DOI
  • Copyright Information Springer Nature Switzerland AG 2020
  • Publisher Name Springer, Cham
  • eBook Packages Biomedical and Life Sciences Biomedical and Life Sciences (R0)
  • Hardcover ISBN 978-3-030-34520-4
  • Softcover ISBN 978-3-030-34523-5
  • eBook ISBN 978-3-030-34521-1
  • Series ISSN 0065-2598
  • Series E-ISSN 2214-8019
  • Edition Number 1
  • Number of Pages XVIII, 885
  • Number of Illustrations 61 b/w illustrations, 107 illustrations in colour
  • Topics Cancer Research
    Molecular Medicine
  • Buy this book on publisher's site
Industry Sectors
Health & Hospitals
Oncology & Hematology
Consumer Packaged Goods


“This is a very focused book and would likely be of interest primarily to basic scientists such as biochemists and cell biologists, as well as clinicians with investigative interests in numerous diseases that may involve heparanase in their pathogenesis, such as oncologists, hematologists, and nephrologists. … This book will be a valuable resource for investigators with interest in heparanase. It represents a ‘one-stop’ location for data and references on heparanase. I am not aware of other books strictly focused on this subject.” (George M Rodgers, Doody's Book Reviews, October 23, 2020)